Clinical trial
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
NCT07101328 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 28, 2026
- Completion date
- September 30, 2029
- Enrollment
- 215 (estimated)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma, lymphoma, b-cell marginal zone, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, mantle cell, lymphoma, non-hodgkin, waldenstrom macroglobulinemia